




# COVID-19

## GLOBAL CLINICAL TRIAL LANDSCAPE (2024)



**#DYK**  
Did you know?

**COVID-19** is a highly contagious infection caused by the SARS-CoV-2 virus




Marketed COVID-19 drugs focus on **anti-body therapies** targeting the SARS-CoV-2 spike protein (e.g., sotrovimab) and small molecules like **remdesivir**, central to COVID-19 treatment



Phase III trials are advancing novel **anti-body treatments** (e.g., **bamlanivimab**) and **mRNA-based vaccines** (e.g., **Moderna's mRNA-1273.529**), showing promising progress in COVID-19 research

### COVID-19 TRIAL CONTRIBUTIONS

The **Asia-Pacific** region has shorter median recruitment durations and faster recruitment rates than the United States and Europe



The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: [communications@novotech-cro.com](mailto:communications@novotech-cro.com)